23andMe CEO on Her Mission to Shake Up Preventive Care

Home/Innovation/23andMe CEO on Her Mission to Shake Up Preventive Care

23andMe CEO on Her Mission to Shake Up Preventive Care

Here’s a great interview (video and text) from MedScape of Eric Topol with Anne Wojcicki, CEO of 23andMe – from the feature:

topol

Topol with Wojcicki

“Eric J. Topol, MD, talks with Anne E. Wojcicki, co-founder and CEO of 23andMe, about her desire to shake up the practice of medicine by using patients’ genetic data to enhance preventive care and disease treatment. Although the US Food and Drug Administration (FDA) ordered 23andMe to stop marketing its $99 genetic screening tests to consumers last November, Ms. Wojcicki, a Yale-educated biologist, says her company is pressing on with its mission, having already genetically screened some 650,000 people, including Dr. Topol.”

In the segment, Wojcicki emphasizes involving the consumer:

“Every year I would see these glossy brochures that talked about personalized medicine. Everyone had these great quotes about how personalized medicine is coming and the genome project was done, but it wasn’t actually happening. More and more I realized that the consumer — you, the individual — can never make choices; everyone is making choices for you. I was doing research on, ironically, Affymetrix and Illumina, so I started and ended my career with that. I remember talking to Steven McCarroll at the Broad Institute, and he was like a kid in a candy store, saying, “It’s the most exciting time. We are finally getting whole genetic data and it’s inexpensive and reliable. It’s going to change the world.” I kept thinking, if you are going to change the world and usher in personalized medicine, and understand the risks and what you are at risk for, and what you are not at risk for, you have to get the consumer involved.”

The feature

June 7th, 2014|
X